EFPIA Challenges Conclusions Of New EC Report On Drug Pricing
This article was originally published in Scrip
Executive Summary
The European Commission may not have much of a say in drug pricing matters beyond making sure member states meet the requirements of the price transparency directive, but it certainly makes no bones about encouraging countries to act more collaboratively in dealing with the high prices of some new medicines and thereby improving access.